文献速递血液透析通路

抗血小板与抗凝治疗对下肢透析通路的影响

Antiplatelet and Anticoagulation Impact on Patients with Lower Extremity Arteriovenous Dialysis Access.
PubMed 文献 · Ann Vasc Surg · 2026-02-05

基于血管质量倡议(VQI)透析模块2011至2023年数据,回顾性分析1,190例下肢动静脉透析通路患者,其中151例(12.7%)为动静脉瘘(AVF)、1,039例(87.3%)为动静脉移植物(AVG)。

要点

  • 下肢AVG患者出院时单用氯吡格雷与二次通畅率改善相关(HR 0.08,P=0.04)。
  • 阿司匹林、双联抗血小板及单抗+抗凝对下肢AVF/AVG通畅率无显著影响。
  • 下肢AVF组中各出院用药方案间生存率与一期/二期通畅率均无差异。

核心结论

  • 阿司匹林、双联抗血小板治疗及单抗+抗凝对下肢AVF或AVG的生存率与通畅率无显著影响。

研究设计与样本

  • 回顾性分析血管质量倡议(VQI)透析模块2011至2023年所有下肢AVF或AVG患者。
  • 共纳入1,190例,AVF 151例(12.7%),AVG 1,039例(87.3%)。
  • 出院用药分为无药、阿司匹林、氯吡格雷、双联抗血小板治疗(DAPT)、单抗+抗凝(SAPT+AC)。
  • 采用单因素Kaplan-Meier和多因素回归分析评估出院用药对生存及一期/二期通畅率的影响。

主要发现

  • AVF组出院用药分布:无药41例(27.2%)、阿司匹林50例(33.1%)、氯吡格雷5例(3.3%)、DAPT 9例(6.0%)、SAPT+AC 46例(30.5%)。
  • AVG组出院用药分布:无药348例(33.5%)、阿司匹林271例(26.1%)、氯吡格雷59例(5.7%)、DAPT 62例(6.0%)、SAPT+AC 299例(28.8%)。
  • Kaplan-Meier分析显示AVF组各用药方案间生存率、一期通畅率及二期通畅率均无差异。
  • 阿司匹林、DAPT及SAPT+AC对AVG通畅率无显著差异。

临床怎么用

  • 下肢AVG患者出院时可考虑处方氯吡格雷单药抗血小板治疗以延长通路通畅性。
  • 下肢AVF患者出院抗血小板或抗凝治疗未见明确获益,决策需个体化。
  • 需进一步研究下肢透析通路创建后抗血小板药物的使用策略。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • AVF组各用药亚组样本量小(如氯吡格雷仅5例),结果解释需谨慎。
  • 仅分析出院时用药,未涵盖用药依从性及后续调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lower extremity (LE) access remains a last resort for many patients needing dialysis. The role antiplatelet or anticoagulation (AC) therapy play in their patency is unknown. We sought to identify the effects of antiplatelet or AC therapy prescribed at discharge on patency and survival in patients undergoing creation of LE dialysis access. METHODS: All patients in the Vascular Quality Initiative dialysis module with a LE arteriovenous (AV) fistula (AVF) or AV graft (AVG) created from 2011 to 2023 were retrospectively analyzed. Medications prescribed at discharge were organized into aspirin (ASA), clopidogrel, dual antiplatelet therapy (DAPT), and single antiplatelet therapy plus anticoagulation (SAPT + AC). Univariable Kaplan-Meier (KM) and multivariable regression analyses were utilized to assess impact of discharge medication on survival and primary/secondary patency. RESULTS: A total of 1,190 patients underwent LE dialysis access creation with 151 (12.7%) receiving AVFs and 1,039 (87.3%) receiving AVGs. Of AVF patients, 41 (27.2%) were discharged on no medication, 50 (33.1%) on ASA, 5 (3.3%) on clopidogrel, 9 (6.0%) on DAPT, and 46 (30.5%) on SAPT + AC. Following AVG creation, 348 (33.5%) of patients were discharged on no medications, 271 (26.1%) on ASA, 59 (5.7%) on clopidogrel, 62 (6.0%) on DAPT, and 299 (28.8%) on SAPT + AC. KM analyses showed no difference in survival, primary patency, or secondary patency based on medication following AVF. Multivariable analysis showed improved secondary patency with clopidogrel alone (hazard ratio, 0.08; confidence interval, 0.01-0.96; P = 0.04). ASA, DAPT, and SAPT + AC use showed no significant difference. CONCLUSION: This analysis suggests SAPT is protective for LE AVG with clopidogrel alone showing statistically significant protection. This suggests that clopidogrel as SAPT is a viable option for prolonging AVG patency if prescribed at discharge. Further study on antiplatelet usage following LE dialysis access creation is warranted.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Christy G, Ebertz DP, Siracuse JJ, et al. Antiplatelet and Anticoagulation Impact on Patients with Lower Extremity Arteriovenous Dialysis Access. Ann Vasc Surg. 2026. PMID: 41651167. doi:10.1016/j.avsg.2026.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。